Close Menu

NEW YORK – JP Morgan said on Monday afternoon that it is downgrading Illumina from an 'overweight' to a 'neutral' rating following Illumina's announcement earlier in the day that it plans to acquire cancer diagnostics company Grail for $8 billion in stock and cash. The investment bank also lowered its December 2021 price target for Illumina from $390 to $280.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.

Nov
10
Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.